Zai Lab’s (ZLAB) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Zai Lab (NASDAQ:ZLAB) in a report released on Friday morning,Weiss Ratings reports.

Several other research firms also recently weighed in on ZLAB. Wall Street Zen downgraded Zai Lab from a “buy” rating to a “hold” rating in a research report on Friday, June 27th. Citigroup reaffirmed a “buy” rating and set a $69.00 price objective (up from $66.00) on shares of Zai Lab in a research note on Monday, August 11th. Leerink Partners set a $75.00 target price on shares of Zai Lab and gave the company an “outperform” rating in a research note on Monday, June 30th. Finally, Jefferies Financial Group initiated coverage on shares of Zai Lab in a report on Monday, August 25th. They issued a “buy” rating and a $52.00 target price for the company. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $56.35.

Zai Lab Trading Down 6.1%

Shares of NASDAQ:ZLAB opened at $26.32 on Friday. The company has a market cap of $2.94 billion, a price-to-earnings ratio of -12.90 and a beta of 1.08. Zai Lab has a 12 month low of $23.82 and a 12 month high of $44.34. The company has a 50-day moving average price of $31.97 and a 200 day moving average price of $33.31.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). Zai Lab had a negative return on equity of 27.32% and a negative net margin of 49.68%.The company had revenue of $109.98 million for the quarter, compared to analysts’ expectations of $125.66 million. Zai Lab has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Zai Lab will post -2.58 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Ying Du sold 46,387 shares of the firm’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $35.47, for a total value of $1,645,346.89. Following the transaction, the chief executive officer owned 536,962 shares of the company’s stock, valued at $19,046,042.14. This trade represents a 7.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Yajing Chen sold 1,438 shares of Zai Lab stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $35.42, for a total transaction of $50,933.96. Following the sale, the chief financial officer owned 16,720 shares of the company’s stock, valued at $592,222.40. The trade was a 7.92% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 161,562 shares of company stock worth $5,650,256. 4.96% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Zai Lab

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Zai Lab by 46,222.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,132,201 shares of the company’s stock valued at $77,058,000 after acquiring an additional 2,127,598 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Zai Lab by 63.6% during the 1st quarter. Principal Financial Group Inc. now owns 2,884,810 shares of the company’s stock worth $104,257,000 after purchasing an additional 1,121,856 shares during the period. Jennison Associates LLC bought a new stake in Zai Lab during the 1st quarter valued at $25,743,000. Allianz Asset Management GmbH lifted its holdings in shares of Zai Lab by 25.1% in the 1st quarter. Allianz Asset Management GmbH now owns 1,884,411 shares of the company’s stock worth $68,103,000 after buying an additional 378,545 shares during the period. Finally, Frazier Life Sciences Management L.P. purchased a new stake in shares of Zai Lab in the 1st quarter worth $12,649,000. 41.65% of the stock is owned by hedge funds and other institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.